Literature DB >> 26459909

Bisdemethoxycurcumin suppresses migration and invasion of highly metastatic 95D lung cancer cells by regulating E-cadherin and vimentin expression, and inducing autophagy.

Jinhong Xu1, Heping Yang1, Xiangdong Zhou1, Haijing Wang1, Liang Gong1, Chunlan Tang1.   

Abstract

Curcumin is an active component of the medicinal plant turmeric, which has been reported to have anti‑metastatic activities and induce autophagy in numerous cancer types. Bisdemethoxycurcumin (BDMC), one of the major active curcumin derivatives present in turmeric, was previously shown to trigger autophagy in highly metastatic large‑cell lung cancer 95D cells. However, the effects of the induction of autophagy by BDMC on the invasion and migration of 95D cells has remained elusive. Therefore, the present study investigated the effects of BDMC on the invasion and migration of highly metastatic large‑cell lung cancer 95D cells. Meanwhile we observed the effect of autophagy induced by BDMC on the migration and invasion in 95D cells. Transwell assays showed that BDMC exerted an inhibitory effect on the migration and invasion of 95D cells. Furthermore, the expression of vimentin was downregulated, while E‑cadherin expression was upregulated in 95D cells treated with BDMC. In addition, blockage of autophagy through Beclin1‑targeted small interfering RNA attenuated the inhibition of BDMC on 95D-cell migration and invasion. These findings provided direct evidence that BDMC inhibits 95D-cell migration and invasion. Furthermore, the inhibition of 95D-cell migration and invasion was associated with the downregulation of vimentin expression and the upregulation of E‑cadherin expression. Autophagy was involved in the anti‑cancer effects of BDMC on 95D cells. The present study provided novel insight into the underlying mechanisms of the anti-cancer effect of BDMC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26459909     DOI: 10.3892/mmr.2015.4356

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.

Authors:  Yong Hu; Jialan Zang; Xiaobing Qin; Dali Yan; Haixia Cao; Leilei Zhou; Jie Ni; Shaorong Yu; Jianzhong Wu; Ji-Feng Feng
Journal:  Onco Targets Ther       Date:  2017-04-28       Impact factor: 4.147

2.  High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database.

Authors:  Le Du; Jingchuan Li; Lei Lei; Hongjuan He; Erfei Chen; Jing Dong; Jin Yang
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

3.  Preparation of poly(lactide-co-glycolide) microspheres and evaluation of pharmacokinetics and tissue distribution of BDMC-PLGA-MS in rats.

Authors:  Guozhuan Li; Liang Yao; Jing Li; Xiaoyan Qin; Zhen Qiu; Weidong Chen
Journal:  Asian J Pharm Sci       Date:  2017-10-10       Impact factor: 6.598

Review 4.  Liver X Receptor as a Possible Drug Target for Blood-Brain Barrier Integrity.

Authors:  Mahsa Eskandari; Ali Awsat Mellati
Journal:  Adv Pharm Bull       Date:  2021-08-14

5.  Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination.

Authors:  Chengjiang Qiu; Kairui Liu; Sheng Zhang; Simin Gao; Weirun Chen; Dateng Li; Youxing Huang
Journal:  Drug Des Devel Ther       Date:  2020-03-05       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.